Zacks Investment Research on MSN

J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELOâ„¢ ...
The American Journal of Managed Care

FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...